Nationwide Fund Advisors cut its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 9.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,625 shares of the biotechnology company’s stock after selling 5,905 shares during the period. Nationwide Fund Advisors owned approximately 0.12% of bluebird bio worth $7,777,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the stock. Dimensional Fund Advisors LP boosted its holdings in bluebird bio by 24.5% during the first quarter. Dimensional Fund Advisors LP now owns 84,961 shares of the biotechnology company’s stock valued at $7,723,000 after acquiring an additional 16,741 shares during the period. Bank of Montreal Can boosted its holdings in bluebird bio by 118.9% during the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after acquiring an additional 911 shares during the period. Aperio Group LLC boosted its holdings in bluebird bio by 10.9% during the second quarter. Aperio Group LLC now owns 5,001 shares of the biotechnology company’s stock valued at $525,000 after acquiring an additional 491 shares during the period. Russell Investments Group Ltd. boosted its holdings in bluebird bio by 15.0% during the second quarter. Russell Investments Group Ltd. now owns 38,882 shares of the biotechnology company’s stock valued at $4,084,000 after acquiring an additional 5,059 shares during the period. Finally, Strs Ohio boosted its holdings in bluebird bio by 25.4% during the second quarter. Strs Ohio now owns 7,400 shares of the biotechnology company’s stock valued at $777,000 after acquiring an additional 1,500 shares during the period.
A number of equities research analysts have issued reports on the stock. Evercore ISI assumed coverage on shares of bluebird bio in a report on Wednesday, August 16th. They set an “in-line” rating and a $102.00 price target for the company. Wells Fargo & Company reiterated an “outperform” rating and issued a $158.00 target price (up previously from $134.00) on shares of bluebird bio in a research note on Tuesday, September 5th. Maxim Group reiterated a “buy” rating and issued a $170.00 target price (up previously from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. Morgan Stanley cut shares of bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 target price for the company. in a research note on Monday, October 2nd. Finally, Barclays assumed coverage on shares of bluebird bio in a research note on Wednesday, September 6th. They issued an “overweight” rating and a $151.00 target price for the company. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $138.45.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The business had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. During the same period last year, the company earned ($2.07) EPS. The business’s revenue for the quarter was up 397.4% on a year-over-year basis. sell-side analysts anticipate that bluebird bio, Inc. will post -6.68 earnings per share for the current fiscal year.
In related news, insider Jeffrey T. Walsh sold 4,900 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $125.73, for a total value of $616,077.00. Following the completion of the transaction, the insider now owns 32,205 shares of the company’s stock, valued at $4,049,134.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Susanna Gatti High sold 1,282 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $172.15, for a total transaction of $220,696.30. Following the completion of the transaction, the chief operating officer now directly owns 13,718 shares of the company’s stock, valued at approximately $2,361,553.70. The disclosure for this sale can be found here. Insiders sold 110,450 shares of company stock valued at $15,790,373 in the last three months. Company insiders own 3.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://sportsperspectives.com/2017/12/10/nationwide-fund-advisors-sells-5905-shares-of-bluebird-bio-inc-blue.html.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.